Imperial College London
Alternate

Professor Neil Poulter

Faculty of Medicine, School of Public Health

Professor of Preventive Cardiovascular Medicine.
 
 
 
//

Contact

 

+44 (0)20 7594 3446n.poulter

 
 
//

Assistant

 

Mrs Ranjit Rayat +44 (0)20 7594 3445

 
//

Location

 

55Stadium HouseWhite City Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Mann:2018:10.1161/CIRCULATIONAHA.118.036418,
author = {Mann, JFE and Fonseca, V and Mosenzon, O and Raz, I and Goldman, B and Idorn, T and von, Scholten BJ and Poulter, NR},
doi = {10.1161/CIRCULATIONAHA.118.036418},
journal = {Circulation},
pages = {2908--2918},
title = {Effects of liraglutide versus placebo on cardiovascular events in patients with type 2 diabetes mellitus and chronic kidney disease},
url = {http://dx.doi.org/10.1161/CIRCULATIONAHA.118.036418},
volume = {138},
year = {2018}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - BACKGROUND: LEADER trial (Liraglutide Effect and Action in Diabetes: Evaluation of CV Outcome Results) results demonstrated cardiovascular benefits for patients with type 2 diabetes mellitus at high cardiovascular risk on standard of care randomized to liraglutide versus placebo. The effect of glucagon-like peptide-1 receptor agonist liraglutide on cardiovascular events and all-cause mortality in patients with type 2 diabetes mellitus and chronic kidney disease is unknown. Liraglutide's treatment effects in patients with and without kidney disease were analyzed post hoc. METHODS: Patients were randomized (1:1) to liraglutide or placebo, both in addition to standard of care. These analyses assessed outcomes stratified by baseline estimated glomerular filtration rate (eGFR; <60 versus ≥60 mL/min/1.73 m2) and baseline albuminuria. The primary outcome (composite of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke) and secondary outcomes, including all-cause mortality and individual components of the primary composite outcome, were analyzed using Cox regression. RESULTS: Overall, 2158 and 7182 patients had baseline eGFR <60 or ≥60 mL/min/1.73 m2, respectively. In patients with eGFR <60 mL/min/1.73 m2, risk reduction for the primary composite cardiovascular outcome with liraglutide was greater (hazard ratio [HR], 0.69; 95% CI, 0.57-0.85) versus those with eGFR ≥60 mL/min/1.73 m2 (HR, 0.94; 95% CI, 0.83-1.07; interaction P=0.01). There was no consistent effect modification with liraglutide across finer eGFR subgroups (interaction P=0.13) and when analyzing eGFR as a continuous variable (interaction P=0.61). Risk reductions in those with eGFR <60 versus ≥60 mL/min/1.73 m2 were as follows: for nonfatal myocardial infarction, HR, 0.74; 95% CI, 0.55-0.99 versus HR, 0.93; 95% CI, 0.77-1.13; for nonfatal stroke, HR, 0.51; 95% CI, 0.33-0.80 versus HR, 1.07; 95% CI, 0.84-1.37; for cardiovascular death, HR, 0.67; 95% CI, 0.50-0.90 ver
AU  - Mann,JFE
AU  - Fonseca,V
AU  - Mosenzon,O
AU  - Raz,I
AU  - Goldman,B
AU  - Idorn,T
AU  - von,Scholten BJ
AU  - Poulter,NR
DO  - 10.1161/CIRCULATIONAHA.118.036418
EP  - 2918
PY  - 2018///
SN  - 0009-7322
SP  - 2908
TI  - Effects of liraglutide versus placebo on cardiovascular events in patients with type 2 diabetes mellitus and chronic kidney disease
T2  - Circulation
UR  - http://dx.doi.org/10.1161/CIRCULATIONAHA.118.036418
UR  - https://www.ncbi.nlm.nih.gov/pubmed/30566006
UR  - http://hdl.handle.net/10044/1/66024
VL  - 138
ER  -
Download